Finance & Investment (Pharma & Healthcare)


Finance and Investment (Pharma and Healthcare) Market Research Reports Analysis and Trends

The Finance and Investment in Pharma and Healthcare industry gives information on budgets, supplier selection criteria, business challenges and investment opportunities of leading purchase decision makers. The report also gives information on future growth of buyers and suppliers, e-procurement, opinions and strategies of business decision makers and competitors, business priorities, company type and sizes respectively, market analysis of the pharmaceutical company.

The Key features of Finance and Investment in Pharma and Healthcare industry reports are:  

  • Profits growth and future developments in business structure of pharmaceutical industry.
  • Merger and acquisition activity of Pharma companies.
  • Capital expenditure and change in staff recruitment activity in Pharma companies.
  • Key regions of growth within the company.
  • Key industry threats and opportunities of pharmaceutical industry.
  • Key supplier actions and e-procurement.
  • Annual procurement budgets and change in procurement expenditure.
  • Change in supplier selection and procurement objectives of the company.
  • Costs involved in various pharmaceutical company products.
Publication Single User License (PDF) Price
OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017

OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017

Date Published: Sep 30 2013

OpportunityAnalyzer: Nonalcoholic Steatohepatitis (NASH) - Opportunity Analysis and Forecasts to 2017

Summary

$5,995.00
OpportunityAnalyzer: Opioid-Induced Constipation - Opportunity Analysis and Forecasts to 2017

OpportunityAnalyzer: Opioid-Induced Constipation - Opportunity Analysis and Forecasts to 2017

Date Published: Sep 30 2013

OpportunityAnalyzer: Opioid-Induced Constipation - Opportunity Analysis and Forecasts to 2017

Summary

$5,995.00
Medical Devices Contract Research Organizations

Medical Devices Contract Research Organizations - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018

Date Published: Jun 7 2012
Medical Devices Contract Research Organizations - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2018
 
Summary
 
$3,995.00
Pharmaceutical Leaders 2012

Pharmaceutical Leaders 2012 - Key Trends, Emerging Strategies and Financial Analysis of the Top Performers

Date Published: Jul 24 2012
Pharmaceutical Leaders 2012 - Key Trends, Emerging Strategies and Financial Analysis of the Top Performers
 

Summary

 
$3,995.00
PharmaLeaders: Innovative Mid-Cap Biotechnology Benchmark Report - Financial Benchmarking, Pipeline Assessment & Competitive Analysis of Innovative Biotechs

PharmaLeaders: Innovative Mid-Cap Biotechnology Benchmark Report - Financial Benchmarking, Pipeline Assessment & Competitive Analysis of Innovative Biotechs

Date Published: Jan 31 2013
PharmaLeaders: Innovative Mid-Cap Biotechnology Benchmark Report Financial Benchmarking, Pipeline Assessment & Competitive Analysis of Innovative Biotechs
 

Summary

$3,995.00
Biologics in the Emerging Markets - Ripe For Realization of the Commercial Potential - But Hurdles Still to Overcome

Biologics in the Emerging Markets - Ripe For Realization of the Commercial Potential - But Hurdles Still to Overcome

Date Published: Sep 15 2012

Biologics in the Emerging Markets - Ripe For Realization of the Commercial Potential - But Hurdles Still to Overcome

Summary

Biologics cover a diverse range of products and deliverables and have revolutionized the treatment of many diseases. The complexity of biologics has made their manufacture an expensive and lengthy process which has hindered uptake in many less developed healthcare markets. However, the global biologics market is rapidly growing and was estimated to be worth over $130 billion in 2010.

$3,900.00
Biopharma M&A and Deal Making - Understanding the Latest Trends to Optimize Future Strategy

Biopharma M&A and Deal Making - Understanding the Latest Trends to Optimize Future Strategy

Date Published: Mar 15 2013

Biopharma M&A and Deal Making - Understanding the Latest Trends to Optimize Future Strategy

Summary

$3,900.00
Electronic Medical Records Market to 2017

Electronic Medical Records Market to 2017 - Government Financial Incentives and Benefits in terms of Costs and Quality of Healthcare Drive Adoption among Physicians and Hospitals

Date Published: Mar 31 2012

Electronic Medical Records Market to 2017 - Government Financial Incentives and Benefits in terms of Costs and Quality of Healthcare Drive Adoption among Physicians and Hospitals

 

Summary

 
$3,500.00
Emerging Pharmaceutical Market in Indonesia and Philippines 2012

Emerging Pharmaceutical Market in Indonesia and Philippines - 100% Foreign Direct Investment in Indonesia and Extensive Insurance Coverage in the Philippines Attract Foreign Pharma Companies

Date Published: Jun 4 2012
Emerging Pharmaceutical Market in Indonesia and Philippines - 100% Foreign Direct Investment in Indonesia and Extensive Insurance Coverage in the Philippines Attract Foreign Pharma Companies
 

Summary

 
$3,500.00
Top 20 Contract Research Organizations (CRO)

Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets

Date Published: Sep 1 2011
Top 20 Contract Research Organizations (CRO) - Asia-Pacific, Especially India and China, Positioned to Benefit from Rising Financial and Regulatory Pressures in Western Pharmaceutical Markets
 
Summary
 
$3,500.00
Non-public hospitals market in Central Europe 2013

Non-public hospitals market in Central Europe 2013

Date Published: Mar 1 2013

Central European healthcare receptive to expansion of non-public hospitals

$3,500.00
Pharmaceutical Pricing and Reimbursement in China 2012

Pharmaceutical Pricing and Reimbursement in China - Series of Mandated Price Cuts Not Effective in Stemming Healthcare Expenditures

Date Published: Jun 12 2012
Pharmaceutical Pricing and Reimbursement in China - Series of Mandated Price Cuts Not Effective in Stemming Healthcare Expenditures
 
Summary
 
$3,500.00
Workforce Reductions in Pharmaceuticals

Workforce Reductions in Pharmaceuticals - Outsourcing, External Innovation and Collaboration Will Drive the Industry Forward

Date Published: Jun 12 2012
Workforce Reductions in Pharmaceuticals - Outsourcing, External Innovation and Collaboration Will Drive the Industry Forward
 
Summary
 
$3,500.00
Biological Strategies in the Emerging Markets Report On BRIC

Biological Strategies in the Emerging Markets - BRIC Countries Will Underpin Future Pharma Growth

Date Published: Jun 12 2012

Biological Strategies in the Emerging Markets - BRIC Countries Will Underpin Future Pharma Growth

$3,500.00
PharmaSphere: Emerging Biotech Investment Report - Strategic Trends in Private Equity and Venture Capital Funding

PharmaSphere: Emerging Biotech Investment Report - Strategic Trends in Private Equity and Venture Capital Funding

Date Published: Mar 12 2014

PharmaSphere: Emerging Biotech Investment Report - Strategic Trends in Private Equity and Venture Capital Funding

Summary

$2,995.00
Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma

Global Pharmaceutical & Biotechnology Outlook 2013: Global Pharma

Date Published: Jan 1 2013

Over the next five years, we will witness surge in approval of new drugs that would deliver a major improvement in the standard of care. Therapy areas - Oncology, Diabetes, Ophthalmology HCV, Atrial Fibrillation, Multiple Sclerosis, Dyslipidemia, Alzheimer’s and Melanoma are few select areas where newer therapies that are safer and more efficacious will reach the market. Many of these innovations promise a paradigm shift in the standard of care.

$2,500.00
Global Pharmaceutical and Biotechnology Outlook 2014 :Rising Stars

Global Pharmaceutical and Biotechnology Outlook 2014 :Rising Stars

Date Published: Jan 14 2014
$2,500.00
Global Pharmaceutical & Biotechnology Outlook 2013: Rising Stars

Global Pharmaceutical & Biotechnology Outlook 2013: Rising Stars

Date Published: Jan 2 2013

Innovative and improved drugs therapies developed through novel target discovery and technology platforms have originated from the backyards of small research focused companies (Rising Stars, RS, non-profitable biotech companies). The universe continues to grow despite the high risk and the wait to transform into a successful profitable Mature Biotech is long. 2012 saw new drugs approvals for unmet needs, first in class drugs for Anti-obesity, Myelofibrosis, cancers and better drug options for HCV, RA, MS, psoriasis, HCC, dyslipidemia etc.

$2,500.00
Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech

Global Pharmaceutical & Biotechnology Outlook 2014: Mature Biotech

Date Published: Jan 14 2014
$2,500.00
Global Pharmaceutical & Biotechnology Outlook 2013: Mature Biotech

Global Pharmaceutical & Biotechnology Outlook 2013: Mature Biotech

Date Published: Jan 2 2013

Macro Analysis
• Performance of the Mature Biotech companies recommended by MP Advisors
in 2012 -report card is very impressive and we expect the positive sentiments
to prevail in 2013 and beyond
• Valuation Multiples and Fundamentals- Drivers of Growth.
• MP Advisors’ Proprietary Sum-of-The-Parts Valuation and Top Picks for 2013
• Drug Approvals 2012-15
• Key Milestones During 2013/14
• Impact on revenue 2012-2017 from Patent Expiry and Strategies deployed to
meet the challenges.
• Pipeline of Biosimilar mAbs

$2,500.00

Pages

Shopping cart

0 Items $0.00
Market Research Special Offers
Not able to find what you are looking for?
Call Us
WHY CHOOSE MARKET RESEARCH REPORTS?
1
Trusted By Leaders
2
Shop With Confidence
3
Customer Centric
4
Personalized Solutions
5
Secure Checkout

User login

Clients Who Trust Us

Orange, Google, Microsoft, Barclays, CassidianB. Braun, Cobham, fiserv, Harris, Wipro, AonMunich Re, Lotte Chemical, National Post, First Data